Sharechat Logo

ArborGen Holdings Limited (NZX: ARB) Updates Market on FY22 Guidance

Friday 21st January 2022

Text too small?

In November 2021, ArborGen Holdings Limited (NZX: ARB ) (the Company) announced guidance of US GAAP EBITDA in the range of US$11.3 to $11.7 million for the fiscal year ending 31 March 2022 (FY22) subject to any future impact from supply chain and COVID related issues in the US. Since then the pandemic, including the recent emergence of Omicron, is continuing to cause significant disruptions in the industry ranging from transportation issues to labour shortages.

Accordingly the Company has re-estimated guidance of US GAAP EBITDA to be in the range of US$9.5 to US$10.5 million assuming a certain level of seedlings remain unsold. Almost all of this reduction in EBITDA is from a shortfall in sales of lower margin Open Pollinated (OP) seedlings.

The Company is pleased to confirm that it continues to be on track to deliver its highest Mass Control Pollinated (MCP) sales year in the US this year, with orders tracking 30+% higher than the fiscal year ending March 2021.

Please see the link below for details

ArborGen Holdings Updates Market on FY22 Guidance

Source: ArborGen Holdings Limited

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Turners delivers record earnings result for FY22
NPH - 2022 Half Year Results
24th May 2022 Morning Report
Ryman Healthcare plans new village in Rolleston
My Food Bag releases FY22 Results
Oceania positioned for growth
Ryman Healthcare buys retirement village site in Melbourne
Dr David Kerr to retire from Ryman Healthcare Board
20th May 2022 Morning Report